Abstracts

TRAJECTORY ANALYSIS OF COGNITIVE OUTCOMES IN CHILDREN WITH PERINATAL HIV

Cognitive impairment is common in children with perinatal HIV (pHIV). HIV-related neuropathogenesis may produce distinct cognitive phenotypes as children age. We used trajectory modeling to identify clusters of children with pHIV following unique developmental trajectories and identified predictors of belonging to select cognitive trajectory groups. Participants included Thai and Cambodian children with pHIV enrolled in…

SYSTEMIC INFLAMMATION AND STRUCTURAL BRAIN CHANGES IN PERINATALLY HIV+ ADOLESCENTS

Neurological impairments despite ART are well documented in perinatally-infected HIV+ adolescents (PHIV) but the mechanisms that drive this are not well defined. Systemic inflammation may be one mechanism but this has not been investigated in adolescence when the brain is undergoing rapid development. Baseline data were drawn from the Cape Town Adolescent Antiretroviral Cohort (CTAAC).…

GENOMICS LINKS AUTOPHAGY WITH NEUROCOGNITIVE IMPAIRMENT IN HIV-INFECTED CHILDREN

HIV associated neurocognitive impairment (NCI) is a common complication of perinatal HIV infection and is associated with elevated markers of inflammation. Here we identified host genetic variants associated with NCI in HIV-infected children (2 mo-18 yrs). Whole exome sequencing was performed on 195 HIV-infected children with NCI (standardized global cognitive score for age (CSA) <70)…

HIGH PRESCRIPTION ERROR RATES AMONG CHILDREN ON ANTIRETROVIRAL THERAPY IN KENYA

Access to life saving antiretroviral therapy (ART) in many resource-limited settings has increased, yet more than 30% of children on ART do not achieve viral suppression. Infants and children require continuous medication dose adjustments in response to changing pharmacodynamics, and inappropriate dosing may contribute to viral non-suppression. This study sought to determine the magnitude of…

PK AND 4-WEEK OUTCOMES OF DOLUTEGRAVIR DISPERSIBLE TABLETS IN HIV-INFECTED CHILDREN

Dolutegravir (DTG, S/GSK1349572) is recommended as first-line treatment for HIV-infected adults and children 6 yrs and older due to its potency, high barrier to resistance, convenience and tolerability. A 5mg dispersible tablet (DTG-DT) formulation for children is being evaluated in IMPAACT P1093 (NCT01302847), an ongoing phase I/II open-label dose-finding study. The first DTG-DT dosing tested…